Malika Ammam, PhD,  —

Malika Ammam received her MS degree from the University of Pierre et Marie CURIE in July 2002 and her PhD from the University of Paris Sud XI, France in September 2005. From 2006 to 2007, she worked as a research fellow at the University of Kansas in collaboration with Pinnacle Technology Inc. (USA). From 2007 to 2010, she was a research associate at KU Leuven, Belgium. From 2010 to 2012, she worked at the University of Ontario Institute of Technology in collaboration with Alcohol Countermeasure Systems Corporation, Canada. She held a prestigious Rosalind Franklin fellowship and resigned in 2015. Now, she is a freelancer.

Articles by Malika Ammam

Laurent Pharmaceuticals Awarded $3M to Initiate Phase 2 Study of Oral CF Therapy

The Cystic Fibrosis Foundation Therapeutics (CFFT) recently awarded Laurent Pharmaceuticals a Therapeutics Development Award, valued to up to $3 million, to support a Phase 2 clinical trial evaluating the company’s drug candidate, LAU-7b, as a potential treatment for cystic fibrosis (CF). “People with CF have an exaggerated and persistent inflammatory response to…

Alcresta Launches Relizorb for Cystic Fibrosis Feeding Through G-Tubes

Alcresta Therapeutics recently launched the commercialization of the digestive enzyme cartridge Relizorb to help patients unable of breaking down fats, particularly adults with cystic fibrosis (CF) who depend on enteral nutrition. Cystic fibrosis is a life-threatening genetic condition caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene…

CF Researchers Identify Way to Move Key Mutant Protein to Its Proper Spot in Cells

Collaborative research between Eindhoven University of Technology (Netherlands), McGill University (Canada), and the University of Duisburg-Essen (Germany) has identified a promising approach that could lead to the development of an efficient treatment for cystic fibrosis (CF). The paper, “Characterization and small-molecule stabilization of the multisite tandem binding between 14-3-3…

PEP Devices Can Help Reduce CF Pulmonary Flare-ups, Review Finds

A review study suggests that positive expiratory pressure (PEP) devices are more effective than other airway clearance approaches in reducing pulmonary exacerbations in patients with cystic fibrosis (CF), but of similar effectiveness in other measures, like lung function and mucus drainage. The study, entitled “Positive expiratory pressure physiotherapy for airway clearance in people with cystic…

Quest Diagnostics Presents Findings on Clinical Value of Genetic Tests to Detect, Predict CF at #ASHG

Quest Diagnostics recently announced findings from several research projects detailing the clinical value of genetic tests to help predict or detect diseases. Data from the studies, which are being presented at the 2015 American Society of Human Genetics (ASHG) Annual Meeting being held Baltimore, Maryland from October 8-10, 2015, show that screening…